ServiziMenu principale

<< Torna a "Tutti gli studi"

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations - INCB54828-207 (FIGHT-207)

Studio Clinico

Patologia: Carcinoma della prostata, Carcinoma della vescica, Epatocarcinoma, Neoplasie della mammella, Neoplasie del polmone, Neoplasie dello stomaco, Tumore del testicolo, Tumori del colon retto, Tumori dell’esofago, Tumori del rene, Tumori dell’utero, Tumori dell’ovaio, Altre neoplasie

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico

Randomizzato: No

Fase di studio: II

Richiesta mandatoria di tessuto: 

Linee di trattamento: Seconda linea

Criteri di inclusione: 

- Histologically or cytologically confirmed solid tumor malignancy that is advanced or metastatic or is surgically unresectable.
- Radiographically measurable disease (per RECIST v1.1 or RANO for primary brain tumors). Tumor lesions located in a previously irradiated area or in an area subjected to other loco-regional therapy are considered measureable if progression has been clearly demonstrated in the lesion.
- Documentation of an FGFR1-3 gene mutation or translocation.
- Objective progression after at least 1 prior therapy and no therapy available that is likely to provide clinical benefit. Participants who are intolerant to or decline the approved therapy are eligible only if they have no therapy available that is likely to provide clinical benefit.
- Eastern Cooperative Oncology Group performance status 0 to 2.
- Baseline archival tumor specimen (if less than 24 months from date of screening) or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. Must be a tumor block or approximately 15 unstained slides from biopsy or resection of primary tumor or metastasis.
- Willingness to avoid pregnancy or fathering children.

Criteri di esclusione: 

- Prior receipt of a selective FGFR inhibitor in the past 6 months.
- Receipt of anticancer medications or investigational drugs for any indication or reason within 28 days before first dose of pemigatinib.
- Cannot be a candidate for potentially curative surgery.
- Current evidence of clinically significant corneal or retinal disorder as confirmed by ophthalmologic examination.
- Radiation therapy administered within 2 weeks of enrollment/first dose of study treatment.
- Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases).
- Known additional malignancy that is progressing or requires active treatment.
- History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues.
- Clinically significant or uncontrolled cardiac disease.
- Active chronic or current infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment within 2 weeks before enrollment (participants with asymptomatic chronic infections on prophylactic treatment are allowed).
- Evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (defined as elevated transaminases or cirrhosis; chronic HBV/HCV infection with no cirrhosis and no elevated transaminases is allowed).
- Known HIV infection.
- Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or five half-lives (whichever is longer) before the first dose of study drug/treatment.
- Women who are pregnant or breastfeeding.

Trattamento sperimentale: 


Trattamento di controllo: 


Centri partecipanti

Nord Italia

Ospedale S.Orsola Malpighi, Università di Bologna
Via Pietro Albertoni 15 - 40138 Bologna - BO


IRCCS Istituto Nazionale dei Tumori
Via Venezian 1 - 20133 Milano - MI


IRCCS Candiolo (TO)
St.Provinciale Km 3,95 SP142 - 10060 Candiolo - TO
Fondazione del Piemonte per l'Oncologia


AOUI Verona - Borgo Roma
Piazzale Ludovico Antonio Scuro 10 - 37134 Verona - VR


Centro Italia

Istituto Nazionale Tumori “Regina Elena”
Via Elio Chianesi 53 - 00144 Roma - RM


Sud Italia e isole

Istituto Nazionale Tumori IRCCS Fondazione Pascale
Via Mariano Semmola - 80131 Napoli - NA

Informazioni Generali


Numero di iscrizione a registro: 2018-004768-69

Data di inserimento: 11.06.2021


Incyte Corporation



Principal Investigator ITALIA

Istituto Nazionale Tumori IRCCS - Fondazione Pascale, Napoli

Riferimento: Dr. non disponibile

Telefono: 00000


Localita: Napoli


<< Torna a "Tutti gli studi"